The Oncodetect MRD test utilises whole-genome sequencing to monitor circulating tumour DNA during and after therapy.

Abbott’s next-gen Oncodetect molecular residual disease (MRD) test detects traces of circulating tumor DNA in a patient’s ...

Abbott's new Oncodetect test combines whole-genome sequencing and MAESTRO technology to improve detection of circulating ...

Dr. Rick Baehner, Abbott’s chief medical officer for precision oncology, spoke to MedTech Dive about how the new version of the Oncodetect test performs and the market it addresses.

For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone? Even after treatment, small amounts of cancer may remain in the body at levels that can be ...

New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has highlighted the value of minimal residual disease (MRD) testing in ...

For more than 12 years, Abbott's cancer diagnostics business has helped expand access to colorectal cancer screening through ...

Abbott Laboratories (Abbott), a world-leading medical devices and healthcare company, is one of the leaders in Covid-19 testing with its three diagnostic PCR tests: the ID NOW, m2000, and Alinity m.

Abbott Laboratories is hoping to broaden its reach by appealing to healthy consumers with its new wearable device called Lingo. CEO Robert Ford said Abbott will continue to solve medical problems, ...

Abbott introduces whole-genome sequencing Oncodetect MRD test to detect traces of cancer during and after treatment: Abbott Park, Illinois Wednesday, October 28, 2026, 16:00 Hrs [ ...